Lynparza
-
February 18, 2022
Olaparib Shows Promise for Castrate-Resistant Prostate Cancer Bookmark
George Lundberg, MDThis Business Wire press release announces results from a clinical trial indicating that adding the drug olaparib (brand name Lynparza) to treatment for castrate-resistant prostate cancer enhanced disease-free progression, regardless of biomarker status.
.
-
April 12, 2021
Long-Term Survival Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost Bookmark
George Lundberg, MDCancer Network reports results from 5 years of follow up for a clinical trial in which the drug olaparib (Lynparza) was given to people who had already been treated for relapsed, high-grade serous, or endometrioid ovarian cancer—including primary peritoneal or fallopian tube cancer. Overall survival data show that olaparib outperformed a placebo drug for these patients, suggesting the possibility that it could be an effective “maintenance therapy.”
.
-
December 3, 2020
Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate Cancer Bookmark
George Lundberg, MDA news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.
.
-
May 30, 2020
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
April 9, 2020
FDA Approves Pancreatic Cancer Drug Treatment After It Was Shown to Increase Progression Free Survival Bookmark
George Lundberg, MDArticle from Good News Network curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved the use of Lynparza (olaparib) for treating stage 4 pancreatic cancer patients with hereditary BRCA mutation who have not progressed on platinum therapy. A clinical trial showed prolongation of progression free survival in this subset of patients.
Go to full article published by Good News Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 7, 2020
FDA Approves Lynparza as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer Bookmark
George Lundberg, MDArticle from The Cancer Letter curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza) for marketing and sales for a narrow group of metastatic pancreatic cancer patients, based on rates of progression-free survival in a clinical trial published in The New England Journal of Medicine.
Go to full article published by The Cancer Letter.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.